Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck
Bio Pharma Dive
SEPTEMBER 30, 2021
The acquisition is notable for Merck, which is under pressure to diversify its business beyond the cancer drug Keytruda and has typically favored smaller buyouts.
Let's personalize your content